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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of this review is to assess the effects of non-operative treatments such as hip spica or traction, and surgical
treatments such as pinning in situ and open reduction and fixation for the treatment of slipped upper femoral epiphysis (SUFE).
Secondary objectives include; assessing the effects of timing of the surgery on the outcome AVN, assessing the effects of prophylactic
fixation of the contralateral unaffected side and finding predictors for development of contralateral slips in patients with SUFE.
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B A C K G R O U N D
Description of the condition
Although a rare condition, slipped upper femoral epiphysis
(SUFE) is one of the most common types of paediatric and ado-
lescent hip disorder. SUFE involves instability of the growth plate
(often called the physis) at the junction between the head and neck
of the thigh bone (femur) resulting in the head of the femur stay-
ing in the acetabulum and the neck slipping forward and outward.
Although, the cause is poorly understood, several anatomical fea-
tures and medical conditions have been implicated. The following
features lead to an increase in the shear forces across the physis and
can lead to SUFE (Herring 2008):
1. increased weight (> 80th centile);
2. femoral retroversion (> 10º);
3. increased physis height due to widened hypertrophic zone;
4. more vertical slope of the physis; and
5. trauma.
Medical conditions associated with SUFE include endocrine dis-
orders, renal failure osteodystrophy and previous radiation therapy
(Loder 2000). About 30% of SUFE patients subsequently develop
bilateral SUFE with the other hip slipping as well.
The incidence of SUFE varies with sex, age, and racial group,
with an overall incidence of 10 per 100,000 children. This may
be an under-estimate, as mild cases may not be diagnosed until
arthritis supervenes many years later. SUFE is more common in
boys (75% of cases) with the peak incidence occurring at 12 to 15
years compared to 10 to 13 years in girls. Thus, boys tend to have
their slip two years older than girls (Montgomery 2009). SUFE is
rarely reported after the age of 20 years (Kelsey 1970). The classical
presentation is an overweight child presenting with groin, thigh
or knee pain or both (referred pain, obturator nerve) and limping.
There may be a history of minor trauma. The child may be able
to ambulate (stable slip) or may not be able to do so even with
crutches (unstable slip). If the participant can walk, and there is
an external rotation of the involved limb and it is not possible to
sit comfortably without keeping the leg straight (as the hip cannot
bend). There is usually restriction in the range of movement of
the affected hip. With increasing severity, SUFE is associated with
increasing pain and disability.
Several classifications have been proposed for SUFE.
Functionally, SUFEmay be classified according to weight-bearing
status (Loder 1993) as:
1. stable: patient is able to ambulate and bear their weight; or
2. unstable: patient is unable to ambulate with or without
crutches.
In a case series of 55 SUFEs, Loder showed that avascular necrosis
(AVN) developed in 47% of unstable slips compared to none in
patients with stable slips (Loder 1993). Anatomical reduction of
SUFE occurred in 26 unstable slips (out of 30) and in only two
of the stable slips (out of 25). Loder was not able to demonstrate
an association between early reduction and the development of
AVN. Table 1 provides a glossary of terms associated with slipped
upper femoral epiphysis.
SUFE has been classified chronologically; relating to the onset of
symptoms.
1. Preslip: patient has symptoms with no anatomical
displacement of the femoral head. There may be useful
radiological evidence such as widening of the physis, osteopenia
of the pelvis.
2. Acute: there is an abrupt displacement through the
proximal physis with symptoms and signs developing over a
short period of time (< 3 weeks).
3. Chronic: patients with a chronic slipped capital femoral
epiphysis present with pain in the groin, thigh, and knee that
varies in duration, often ranging from months to years.
4. Acute on chronic: initially, patient has chronic symptoms,
but develops acute symptoms as well following a sudden increase
in the degree of slip.
Radiographical classification is based on the degree of displace-
ment either by proportion of slip, or by the angular displacement
of slip. Wilson 1965 classified slips as:
1. mild slip (grade I) where the displacement of the physis as a
proportion of neck width is less than one third;
2. moderate slip (grade II), displacement is between one third
and one half of neck width; or
3. severe slip (grade III) has displacement of greater than one
half of neck width.
Angular displacement is measured by the Southwick angle of the
slip (Southwick 1967). The angle is measured on the lateral view
of the both hips. It is measured by drawing a line perpendicular to
a line connecting the posterior and anterior tips of the epiphysis
at the physis. The angle between the perpendicular line and the
femoral shaft line is the angle. The angle is measured bilaterally.
The slipped side is then subtracted from the normal side. The
number calculated determines the severity which is classified as:
1. mild slip (Grade I) < 30°;
2. moderate slip (Grade II) is 30° to 50°; or
3. severe slip (Grade III) is > 50°.
In practice, most clinicians tend to use a combination of the Loder
classification and one of the radiographic classifications. There is
some crossover between the classifications but severe slips are more
likely to be unstable (Montgomery 2009).
Most investigators agree that once a SUFEhas beendiagnosed, sur-
gical treatment is indicated to prevent progression of the slip. The
goal of treatment has always been to prevent additional slippage
while avoiding the complications of avascular necrosis (AVN) and
chondrolysis (Loder 2000). Recently, the importance of reducing
the slip has been emphasised in preventing femoro-acetabular im-
pingement (FAI) and premature osteoarthritis (OA) (Dodds 2009;
Ganz 2003).
Description of the intervention
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There is almost a universal consensus about the treatment ofGrade
I and (to a lesser extent) grade II SUFE: placing a single screw
across the growth plate through a very small incision on the thigh
to prevent further slip until growth plate closure. This procedure is
commonly referred to as a percutaneous pinning or pinning in situ
(PIS). Sometimes, more than a single screw is required to prevent
further progression depending on the initial stability, severity and
bone quality. Some advocate multiple smooth pins in very young
affected children (less than 8 years old) to allow for growth (Staheli
2008). The screw must not be removed prior to physeal closure,
otherwise progression of the slipmay resume. The appropriateness
of removal after physeal closure is contended. If the slip is more
severe, a more involved procedure or corrective surgery may be
necessary. Pinning in situ may not be physically possible without
reducing the slip, hence the need for reduction. Forceful closed
reduction of a slipped epiphysis is contraindicated due to high risk
of AVN. Some advocate pinning in situ with a re-alignment pro-
cedure performed at a later date. Others recommend immediate
open reduction and fixation. There are several techniques used to
achieve open reduction and fixation including Dunn’s osteotomy,
Fish osteotomy and surgical dislocation. However, the relative ef-
fectiveness of these techniques is contested.
The timing of operation is controversial. Given the rarity of the
condition, most studies that looked at the timing of surgery and
outcome were underpowered. In a meta-analysis of five studies
(130 unstable SUFEs where 56 were treated within 24 hours and
74 were treated after 24 hours of symptom onset), Lowndes 2009
found that the odds for developingAVN if treatment occurs within
24 hours might be halved for developing AVN when compared
to later treatment, although the difference was not statistically
significant (P = 0.44). Peterson 1997 showed early stabilization
within 24 hours was associated with less AVN (3/42 = 7%) in
comparison with those stabilized after 24 hours (10/49 = 20%).
Kalogrianitis 2007 showed that AVN developed in 50% (8/16)
of unstable SUFE. All but one of these SUFE were treated be-
tween 24 and 72 hours after symptom onset. Kalogrianitis 2007
recommended immediate stabilization of unstable slips present-
ing within 24 hours, or if not possible, delaying the operation for
at least one week. However, consistent with lack of power to in-
form the issue of timing, Loder 1993 noted more AVN in patients
treated within 48 hours compared to those treated after 48 hours
(7/8 versus 7/21).
Prophylactic pinning of the normal contra-lateral side is also con-
troversial. The quoted risk of contralateral slip varies from 18 to
60%. Prophylactic PIS is not free of risk which should be weighed
against the benefit. Both proponents and opponents have some ev-
idence to support their views (Jerre 1994;Herring 2008). Stasikelis
1996 performed a retrospective review of 50 children who pre-
sented with unilateral SUFE to determine parameters that pre-
dict the later development of a contralateral slip. They found the
modified Oxford bone age (a measure of physiological maturity)
strongly correlated with the risk of development of a contralateral
slip; contralateral slip developed in 85% of patients with a score of
16, in 11% of patients with a score of 21, and in no patients with
a score of 22 or more. The modified Oxford bone age is based
on appearance and fusion of the iliac apophysis, femoral capital
physis, and greater and lesser trochanters.
We adopted a pragmatic approach for contralateral pinning where
the following factors play a role in decision making:
1. age of the child (< 10 years is associated with a higher risk
of bilaterality);
2. the aetiology of the slip (renal osteodystrophy and
endocrine disorders have a high incidence of bilaterality);
3. the compliance of the child and family; and
4. the nature of current slip (Severe slip occurred over a very
short period of time with no prodromal symptoms may justify
pinning the other side).
How the intervention might work
The goal of treatment is to prevent additional slippage by pro-
viding mechanical stability using screws or pins while avoiding
the complications of avascular necrosis (AVN) and chondrolysis.
AVN and chondrolysis are the most important and robust out-
comes of SUFE treatment. They are readily identifiable and their
development is a good indicator for a bad outcome. However, the
opposite is not true.
The potential for further slip continues until physeal closure (os-
sification of the growth plate). After physeal healing, there may be
a residual displacement which impair function and quality of life,
whilst the patient is still young. A realignment procedure (such
as trochanteric, subtrochanteric or femoral neck osteotomy) may
improve function in these patients. In older patients with estab-
lished degenerative changes, total hip replacement may be indi-
cated. Reducing the slip provides extra stability, improved func-
tion andmay prevent or reduce long term complications; provided
short term complications such as AVN and chondrolysis do not
occur.
Why it is important to do this review
The management of SUFE is controversial and still evolving with
advancing knowledge, surgical skills and expertise. The infre-
quency of cases, the various classifications in use, the various treat-
ment options, and lack of robust evidence for outcomes, has re-
sulted in the lack of clear, evidence-based recommendations for
treatment (Montgomery 2009). This has led to significant vari-
ations in clinical practice threatening possible optimum care for
this group of patients. There have been a few published attempts
(Loder 2000; Lowndes 2009; Wright 2009) to produce recom-
mendations to treat SUFE (Loder 2000; Lowndes 2009; Wright
2009). However, these attempts lacked a rigorous and structured
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approach of critically appraising the available evidence, which is
the purpose of this review.
O B J E C T I V E S
The primary objective of this review is to assess the effects of non-
operative treatments such as hip spica or traction, and surgical
treatments such as pinning in situ and open reduction and fixa-
tion for the treatment of slipped upper femoral epiphysis (SUFE).
Secondary objectives include; assessing the effects of timing of the
surgery on the outcome AVN, assessing the effects of prophylactic
fixation of the contralateral unaffected side and finding predictors
for development of contralateral slips in patients with SUFE.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or controlled clinical trials
(CCTs) which investigate interventions (listed below) for the treat-
ment of SUFE will be considered for inclusion. Inclusion will be
limited to randomised designs if adequately informative. If nec-
essary inclusion will be extended first to other controlled clinical
trial designs and second to other controlled observational designs
such as controlled before-after studies (CBAs) and interrupted
time series (ITS). The primary outcome (AVN) usually becomes
apparent within a year and is rarely reported after one year. Thus
we will exclude any study that does not have this minimum one
year follow-up. Uncontrolled studies such as case series and case
reports will be excluded.
Types of participants
Children (under 20 years old) with a confirmed diagnosis of SUFE
will be considered for inclusion. Children undergoing revision for
previously failed treatment will be excluded.
Types of interventions
Three interventions for treating SUFEwill be considered; non-op-
erative treatments such as hip spica or traction, pinning in situ and
open reduction and fixation.With a few exceptions, non-operative
treatments have become obsolete as a sole treatment for SUFE.
However, traction may be used temporarily before operative treat-
ment and hip spica may be used to augment unreliable fixation.
Studies of patients who underwent such a combined treatment
will be analysed as a subgroup provided sufficient numbers are
available. Interventions will be assessed as follows.
1. Non-operative treatments such as hip spica or tractions
versus operative treatment.
2. Pinning in situ versus open reduction of the slip.
3. Comparing different open reduction techniques of the slip
such as (Dunn’s, Fish and surgical dislocation).
4. Prophylactic fixation of the other (unaffected) hip versus no
prophylactic fixation.
Types of outcome measures
Major outcomes
1. Avascular necrosis of the head of the femur (as binary
outcome).
2. Chondrolysis (as binary outcome).
Minor outcomes
1. Complications such as infection, nerve palsy, femoro-
acetabular impingement or secondary osteoarthritis.
2. Re-operation rate and the need for future salvage
operations.
3. Survival of the implant until there is no risk of further slip.
4. Health related quality of life measures and functional
measures with validated instruments (e.g. Oxford hip score
Murray 2007, EuroQol Brooks 1996).
5. Pain (e.g. using visual analogue scale).
6. Other validated clinician, parent or patient based
performance scores.
The following outcomes will be included in the summary of find-
ings table for each intervention considered:
1. Avascular necrosis of the femoral head;
2. Chondrolysis;
3. Re-operation rate;
4. Infection;
5. Neurovascular damage;
6. Health related quality of life measures and functional
measures with validated instruments; and
7. Pain score.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Bone, Joint and Muscle Trauma Re-
view Group Specialised Register, the Cochrane Central Register of
Controlled Trials (The Cochrane Library, current issue), MED-
LINE (1966 to present), EMBASE (1980 to present), CINAHL
4Interventions for treating slipped upper femoral epiphysis (SUFE) (Protocol)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(1982 to present), and Science Citation Index (ISIWeb of Science
1987 to present).
Appendix 1 summarises the search strategy for MEDLINE, which
will be modified for the other databases.
Searching other resources
We will search the following web sites to identify additional un-
published and ongoing studies: Current Controlled Trials (http:/
/www.controlled-
trials.com/), Centre Watch (www.centerwatch.com), TrialsCen-
tral (http://www.trialscentral.org/), theUKClinical ResearchNet-
work: Portfolio Database (http://public.ukcrn.org.uk/search/),
and SUMSearch (http://sumsearch.org/).
Wewill hand search the Journal of Bone and Joint Surgery - British
Volume (http://proceedings.jbjs.org.uk/), the Journal of Bone and
Joint Surgery - American Volume (http://www.jbjs.org/), and the
American Academy of Orthopaedic Surgeons (www.aaos.org) for
any relevant publications.
The bibliographies of retrieved trials and other relevant publica-
tions, including reviews andmeta-analyses, will be cross referenced
to identify additional studies.
Data collection and analysis
Selection of studies
Two authors (JB & KT) will independently apply the search strat-
egy to identify citations. Article titles and abstracts will be reviewed
independently (by JB & KT). Where a study appears eligible or
further clarity is required, the full article will be obtained for fur-
ther scrutiny. The two authors will independently assess each full
study report to see whether it meets the inclusion criteria. Where
necessary, authors will be contacted formore information and clar-
ification of data. If there is still a disagreement regarding inclusion,
senior authors (SA, AN, RM and JM) will be consulted and when
no consensus is reached, the study will be excluded.
Data extraction and management
Data will be extracted independently by two authors (JA & KT)
using a piloted form (See Table 2). Discrepancies will be resolved
through discussion. The names of the authors and the institutes
will not be masked.
Assessment of risk of bias in included studies
Two authors (SA, KT) will independently assess the risk of bias
in included studies using the Cochrane risk of bias tool (Higgins
2011). This instrument addresses seven specific domains includ-
ing sequence generation, allocation concealment, blinding of par-
ticipants and personnel, blinding of outcome assessment, incom-
plete outcome data, selective outcome reporting and other poten-
tial sources of bias. Other potential sources of bias include inap-
propriate administration of an intervention (or co-intervention),
contamination, selective reporting of subgroups and fraud (See
Table 3). Each domain will be assessed as ’low risk’ of bias, ’high
risk’ of bias or ’unclear risk’ of bias. Disagreement will be resolved
by consensus. Unclear risk of bias will be assigned if consensus
is not reached. The Newcastle-Ottawa Scale (Wells 2012) will be
used to assess themethodological quality of non-randomised stud-
ies (NRS) (See Table 4 and Table 5).
Measures of treatment effect
Continuous data will be recorded as mean, standard deviation
(SD) and group size for each trial arm, with the treatment effect
being reported as the mean difference (MD) with corresponding
95% confidence interval (95% CI). We will use the mean differ-
ence to summarise trial findings if outcomes are measured in the
same way between trials. We will use the standardised mean dif-
ference (SMD) to compare trials that measure the same outcome
(construct), but use different scales. Dichotomous data will be ex-
pressed as proportions or risks, with the treatment effect reported
as a risk ratio (RR) with 95% CI. Statistical significance will be
set at P < 0.05.
Unit of analysis issues
For cluster randomised trials and body-part randomisation de-
signs, we will conduct the analysis at the same level as the alloca-
tion, using a summary measurement for each cluster (or the par-
ticipants).
Dealing with missing data
Missing datawill be sought from the original authors.Where this is
not possible or data ismissing through loss to follow-up, intention-
to-treat principles will be used. No attempt at imputation will be
made.
Assessment of heterogeneity
Heterogeneity will be identified by visual inspection of the for-
est and funnel plots and quantified using the I2 statistic. Hetero-
geneity manifests itself in poor overlap of confidence intervals in
a forest plot, by scatter beyond 95% confidence bounds in a fun-
nel plot and by scatter beyond the ± 2 lines in a Galbraith plot
(Anzures-Cabrera 2010; Bax 2009). We will carry out statistical
pooling on groups of studies which are considered to be sufficiently
similar. Where heterogeneity is absent or low (I2 = 0% to 25%)
we will use a fixed-effect model; if there is evidence of heterogene-
ity (I2 more than 25%), we will use a random-effects model. If
heterogeneity is very high (I2 over 75%), this will be explored by
checking the data accuracy, and by performing subgroup analy-
sis or sensitivity analysis (Higgins 2003). If there is considerable
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variation in results, and particularly if there is inconsistency in
the direction of effect, we will not quote an average value for the
intervention effect (Deeks 2011).
Assessment of reporting biases
If sufficient studies (10 or more) are identified, we plan to assess
potential publication bias using a funnel plot (Sterne 2001).
Data synthesis
Results of comparable groups of trials will be pooled using a fixed-
effect model. A pooled RR and 95% CI will be calculated for di-
chotomous outcomes. A pooled MD and 95% CI will be calcu-
lated for continuous outcomes. Where findings are substantially
heterogenous (I2 over 75%), they will not be pooled but will be
summarised in a table.
Subgroup analysis and investigation of heterogeneity
Whendata allow, wewill perform sub-group analysis to investigate
the following.
1. Timing of surgery (immediate, within 48 hours, after 48
hours).
2. Mode of fixation (a single screw, multiple screws, multiple
pins, partially threaded or fully threaded screws).
3. Grade of the slip (mild, moderate or severe)
4. Stability of the slip as per Loder’s definition (Stable or
Unstable)
5. Prophylactic fixation of the other (unaffected) hip.
6. Use of bone graft.
7. Gender.
8. Age (younger and older than 8 years of age (Staheli 2008).
Sensitivity analysis
Where appropriate, we plan sensitivity analyses investigating the
effects of allocation concealment, assessor blinding, loss to follow-
up and publication status.
Summary of findings table
The GRADE approach (Schünemann 2011), will be used to as-
sess the quality of the body of evidence supporting each outcome
(Schünemann 2011). A ’Summary of findings’ table will be pro-
duced using the GRADE-pro software. This table will provide key
information regarding the quality of the evidence, the magnitude
of effect of the interventions examined, and the sum of available
data for the main outcomes. The overall quality of the evidence
supporting each outcome will be graded as:
1. High quality: Further research is very unlikely to change
our confidence in the estimate of effect.
2. Moderate quality: Further research is likely to have an
important impact on our confidence in the estimate of effect and
may change the estimate.
3. Low quality: Further research is very likely to have an
important impact on our confidence in the estimate of effect and
is likely to change the estimate.
4. Very low quality:We are very uncertain about the estimate.
The following outcomes will be included in the ’Summary of
findings’ tables:
1. AVN;
2. Chondrolysis;
3. Re-operation rate;
4. Infection rate;
5. Neurovascular damage;
6. Health related quality of life measures and functional
measures with validated instruments; and
7. Pain score.
In addition to the absolute and relative magnitude of effect pro-
vided in the ’Summary of findings’ table, the number needed to
treat (NNT) will be calculated from the control group event rate
(unless the population event rate is known) and the risk ratio us-
ing the Visual RxNNT calculator (Cates 2012). For continuous
outcomes, the NNT will be calculated using the Wells calcula-
tor software available at the CMSG editorial office. The minimal
clinically important difference (MCID) for each outcome will be
determined for input into the calculator.
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A D D I T I O N A L T A B L E S
Table 1. Glossary of Terms
Terms Definition
AVN Avascular necrosis; the death of the bone secondary to the loss of blood supply
Chondrolysis The gradual thinning and subsequent loss of the articular cartilage
Prodromal symptom Prodrome is an early symptom (or set of symptoms) that might indicate the start of a disease before more
specific symptoms occur
Retroversion Pointing backward relative to the front of the body. Normally, the femoral neck is pointing 15º forward
SUFE or SCFE These are the two most common abbreviations for the slipped upper (or capital) femoral epiphysis
Table 2. Data extraction sheet
Study ID
Action
Methods
Allocation:
Blindness:
Duration:
Participants
Group 1 Group 2 Group 3
Age
Sex
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Table 2. Data extraction sheet (Continued)
Side Left
Right
Bilateral
Duration of symptoms
Time to surgery
Severity I
II
III
Stability Stable
Unstable
Interventions
1.
2.
3.
Outcomes Group 1 Group 2 Group 3
AVN
Chondrolysis
Re-operation
Infection
Pain
NV damage
Femoro acetabular impingement
Osteoarthritis
Health related quality of life measures
Functional measures
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Table 2. Data extraction sheet (Continued)
Others
Range of motions Flexion
Extension
Abduction
Adduction
Internal rotation
External rotation
Contralateral
involvement
Number
Time
Severity
Stability
Intervention
Other
Notes
Table 3. Risk of Bias Assessment Tool for Randomised Controlled Studies
Domain Risk Review authors’ judgement examples
Random sequence generation Low Using a computer random number generator
High Sequence generated by odd or even date of birth. Allocation by judgement of
the clinician
Unclear Insufficient information about the sequence generation process to permit
judgement of “Low risk” or “High risk”
Allocation concealment Low Central allocation (including telephone, web-based and pharmacy-controlled
randomisation)
High Allocation using case record number
Unclear Insufficient information to permit judgement of “Low risk” or “High risk”
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Table 3. Risk of Bias Assessment Tool for Randomised Controlled Studies (Continued)
Blinding of participants
and personnel
Low Blinding of participants and key study personnel ensured, and unlikely that
the blinding could have been broken
High Noblinding or incomplete blinding, and the outcome is likely to be influenced
by lack of blinding
Unclear The study did not address this outcome
Blinding of outcome assessment Low Blinding of outcome assessment ensured, and unlikely that the blinding could
have been broken
High No blinding of outcome assessment, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear Insufficient information to permit judgement of “Low risk” or “High risk”
Incomplete outcome data Low No missing outcome data or missing outcome data balanced in numbers
across intervention groups, with similar reasons for missing data across groups
High “As-treated” analysis done with substantial departure of the intervention re-
ceived from that assigned at randomisation
Unclear Insufficient reporting of attrition/exclusions to permit judgement of “Low
risk” or “High risk”
Selective reporting Low The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been reported
in the pre-specified way
High Not all of the study’s pre-specified primary outcomes have been reported
Unclear Insufficient information to permit judgement of “Low risk” or “High risk”
Other sources of bias. Low The study appears to be free of other sources of bias
High Had a potential source of bias related to the specific study design used
Unclear Insufficient information to assess whether an important risk of bias exists
Table 4. Risk of Bias Assessment Tool for Cohort Studies
Domain Items Maximum Number of stars Notes
Selection 1) Representativeness of the exposed
cohort
1 Maximum possible stars is 4
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Table 4. Risk of Bias Assessment Tool for Cohort Studies (Continued)
2) Selection of the non exposed co-
hort
1
3) Ascertainment of exposure 1
4) Demonstration that outcome of
interest was not present at start of
study
1
Comparability Comparability of cohorts on the ba-
sis of the design or analysis
2 Maximum possible stars is 2
Outcome 1) Assessment of outcome 1 Maximum possible stars is 3
2) Was follow-up long enough for
outcomes to occur
1
3) Adequacy of follow up of cohorts 1
Table 5. Risk of Bias Assessment Tool for Case-Control Studies
Domain Items Maximum Number of stars Notes
Selection 1) Is the case definition adequate? 1 Maximum possible stars is 4
2) Representativeness of the cases 1
3) Selection of Controls 1
4) Definition of Controls 1
Comparability Comparability of cohorts on the ba-
sis of the design or analysis
2 Maximum possible stars is 2
Exposure 1) Ascertainment of exposure 1 Maximum possible stars is 3
2) Samemethod of ascertainment for
cases and controls
1
3) Non-Response rate 1
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A P P E N D I C E S
Appendix 1. Search strategies
1 Epiphyses, Slipped/
2 (slipped adj3 upper adj3 femoral adj3 epiphysis).tw.
3 Femur Head/ab, pa, su [Abnormalities, Pathology, Surgery]
4 exp Femur Neck/ab, pa, su [Abnormalities, Pathology, Surgery]
5 SUFE.tw.
6 (slipped adj3 epiphyses).tw.
7 exp Slipped Capital Femoral Epiphyses/
8 SCFE.mp. or SCUFE.tw. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary
concept, rare disease supplementary concept, unique identifier]
9 or/1-8
10 randomized controlled trial.pt.
11 controlled clinical trial.pt.
12 randomized.ab.
13 placebo.ab.
14 drug therapy.fs.
15 randomly.ab.
16 trial.ab.
17 groups.ab.
18 or/10-17
19 exp animals/ not humans.sh.
20 18 not 19
21 9 and 20
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